BIZARRE: 8 | Mind Blowing Facts

Broadcom, Alphabet, Sandisk, Novo Nordisk And Zoom: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock futures rose on Monday, building on Friday’s gains. Optimism is fueled by New York Fed President John Williams‘ suggestion that a December rate cut remains possible.

Benzinga · Nov 25, 2025

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial

The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.

Fortune · Nov 24, 2025

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback.  It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga · Nov 24, 2025

GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis

Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

Fortune · Nov 21, 2025

Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently

It's a tough time for the job market

The Independent UK · Nov 20, 2025

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

MarketBeat · Nov 19, 2025

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

Novo Nordisk's new pricing for its GLP-1 drugs is a strategic pivot to capture a mass market, pressure rivals, and secure long-term market dominance.

MarketBeat · Nov 19, 2025

Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.

International Business Times · Nov 18, 2025

With $199 Price, Ozempic Prescriptions Expected to Soar — Experts Warn of Risks

Novo Nordisk's new $199 offer for Ozempic and Wegovy aims to improve access for obesity and diabetes treatments, but experts warn of potential serious side effects.

International Business Times UK · Nov 18, 2025

Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026.

Benzinga · Nov 17, 2025